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Table 1. Sample Characteristics and Symptom Burden Means
cGVHD
(N5 116)
No cGVHD
(N5 58)
Mean (SD) Mean (SD) P
Age in yrs 49.7 (12.33) 50.6 (15.32) 0.700
Oral Presentations S177especially those with older age, chronic GVHD and recipients of
peripheral blood grafts. The incidence for solid cancers continues
to increase with time and life-long cancer surveillance is warranted
in this population.
Risk factors for solid cancers
Risk factor RR (95%CI) Education in yrs 14.7 (1.85) 14.4 (1.97) 0.340
All symptom items 2.65 (1.69) 1.67 (1.46) \0.0001*Age (years)
Core symptom items 2.34 (1.73) 1.77 (1.62) 0.040*\20 1.0
cGVHD symptom items 3.46 (2.08) 1.39 (1.44) \0.0001*20-40 2.4 (0.7-8.1)
Muscle weakness 3.92 (2.74) 1.57 (1.98) \0.0001*.40 6.2 (1.9-20.4)**
Changes in sexual function 3.70 (3.69) 1.57 (2.70) \0.0001*Chronic GVHD
Skin problems 3.37 (2.99) 0.83 (1.58) \0.0001*No 1.0
Eye problems 3.31 (3.09) 1.22 (2.52) \0.0001*Yes 2.6 (1.5-4.6)**
Joint stiffness of soreness 3.06 (3.20) 1.74 (@.32) 0.006*Graft type
Interference items 3.05 (2.37) 2.38 (2.38) 0.080Bone marrow 1.0Peripheral blood 2.5 (1.3-4.5)**
Number (%) Number (%)GVHD prophylaxisGender 0.023*T-cell depletion (ex-vivo) 1.0
Male 73 (62.9) 26 (44.8)ATG/campath 0.5 (0.1-2.4)
Female 43 (37.1) 32 (55.2)MTX1CSA 0.3 (0.1-0.9)*
Race/Ethnicity 0.472
Black/Hispanic 21 (18.1) 8 (13.8)
White 95 (81.9) 50 (86.2)*P\0.05, **P\0.01.Employment Status 0.433
Employed 48 (41.4) 27 (46.6)
Unemployed 68 (58.6) 31 (53.4)
Marital Status 0.356
Married 82 (70.7) 37 (63.8)
Single 34 (29.3) 21 (36.2)
Performance Status 0.297
Good (0-1) 77 (66.4) 43 (74.1)
Poor (2-4) 39 (33.6) 15 (25.9)
Underlying Disease 0.652
Leukemia 72 (62.1) 38 (65.5)
Lymphoma 33 (28.4) 13 (22.4)
Other 11 (9.5) 7 (12.1)
Donor 0.024*
Related 71 (61.2) 25 (43.1)
Unrelated 45 (38.8) 33 (59.9)
Type of Cells 0.249
Peripheral Stem Cells 83 (71.6) 45 (77.6)
Bone Marrow 29 (25.0) 9 (15.5)
Cord Blood 4 (3.4) 4 (6.8)
Occurrence of Acute GVHD \0.0001*
Yes 77 (66.4) 13 (22.4)
No 39 (33.6) 45 (77.6)
*significant at \0.05 level N5number of subjects P5probability
SD5standard deviation.60
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Significance: Chronic graft-versus-host disease (cGVHD) can
cause debilitating symptoms after allogeneic hematopoietic stem
cell transplantation (alloHSCT). A major barrier to effective
treatment of the symptom burden of cGVHD is inadequate as-
sessment.
Problem and Purpose:The symptom burden of cGVHDcannot be
effectively assessed for research and clinical management without
a psychometrically sound, easily administered measure. The purpose
of this research was to develop a valid, reliable, and sensitive measure
of cGVHD symptom burden, based on the M. D. Anderson Symp-
tom Inventory (core MDASI).
Methods: 116 patients with cGVHD and 58 patients without
cGVHD.3 months after alloHSCT completed the 13 symptom se-
verity and 6 interference items of the core MDASI and 14 additional
cGVHD-specific symptom items, generated from patient interviews
and expert panel ratings. Severity and interference were measured on
a 0-10 scale, with 0 meaning none and 10 meaning the worst imagin-
able. Patients with cGHVD answered a single quality-of-life ques-
tion and 3 days later repeated the symptom burden assessment.
Demographic and disease information was collected on all patients.
Psychometric techniques reduced the number of symptom items and
examined the reliability, validity, and sensitivity of the MDASI for
cGVHD (MDASI-GVH).
Results: Sample demographics, disease characteristics, and symp-
tom severity and interference are shown in Table 1. Five new
cGVHD-related items (see Table 1) were found to be clinically sig-
nificant and were retained in the MDASI-GVH. The reliability in-
dex (Cronbach alpha) and test-retest reliability of all 18 symptom
items were 0.90 and 0.82 respectively and of the 6 interference items
were 0.91 and 0.75 respectively. Factor analysis showed the
cGVHD-related symptom items to be a unique factor. The
MDASI-GVH was sensitive to the presence of cGHVD, was able
to discriminate between patients with good and poor performance
status, and was significantly correlated with patient report of overall
quality of life. Symptom severity explained 77.2% of the variance in
interference, with the core symptoms explaining 76.1% and the
cGVHD-related symptoms explaining 55.9%.Implications: We have validated a new analytic tool, the MDASI-
GVH, for quantifying symptom burden produced by cGVHD.
TheMDASI-GVH has the potential to be utilized for quantitatively
assessing response in cGVHD treatment trials and monitoring the
course of cGVHD in clinical care.LEUKEMIA
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Extramedullary (EM) relapse after allogeneic hematopoietic cell
transplantation (HCT) for acute leukemia has not been extensively
studied. Therefore, we analyzed 365 consecutive patients (pts) who
